By Fineline Cube LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced the completion of a Series A funding round worth tens of millions of yuan. The financing was led by Yipu Capital, with follow-on investments from Qianrong Capital and existing shareholder Northern Light Venture Capital. This capital influx is set to accelerate the clinical development of LanssonPharm’s innovative drugs DM-8021 and LS-196, as well as the domestication of multi-component/multi-phase controlled-release and long-acting injectable drug technology platforms.
Accelerating Clinical R&D and Facility Construction
The funds will also be directed towards launching corresponding market-ready products and completing the construction of the company’s Suzhou park base. With this round of financing, Mr. Lin Xianghong, the founding partner of Yipu Capital, will join the LanssonPharm board of directors.
LS-196: A Potential Game-Changer in Antidepressant Therapy
LS-196, a highly selective enzyme allosteric modulator, has demonstrated clear efficacy and rapid onset of action in preclinical studies. It holds the potential to overcome the clinical challenges of delayed response and drug resistance associated with existing antidepressant medications, targeting the unmet needs of patients in the market. Additionally, several of the company’s high-end dosage forms are in the pre-BE clinical stage, which will significantly enrich the company’s product line and lay a solid foundation for its development.
LanssonPharm’s Commitment to Innovation
Founded in 2012, LanssonPharm is positioned as a leader in the research and development of innovative drugs for neurological and psychiatric diseases. The company has a highly educated, technically proficient, and experienced R&D team, with expertise spanning from small molecule design and synthesis to initial screening, pharmacokinetic evaluation, pharmacological and toxicological assessments, regulatory submissions, and clinical trial supervision. Committed to developing innovative drugs with independent intellectual property rights, LanssonPharm has established a library of over 800 small molecule compounds. The company focuses on developing structurally novel, competitive small molecules for chronic neurological and psychiatric diseases, fostering the launch of new drugs with independent intellectual property and promoting a strategic shift towards independent innovation in the pharmaceutical industry.-Fineline Info & Tech